+

WO2012124998A3 - 바이오핀 - Google Patents

바이오핀 Download PDF

Info

Publication number
WO2012124998A3
WO2012124998A3 PCT/KR2012/001890 KR2012001890W WO2012124998A3 WO 2012124998 A3 WO2012124998 A3 WO 2012124998A3 KR 2012001890 W KR2012001890 W KR 2012001890W WO 2012124998 A3 WO2012124998 A3 WO 2012124998A3
Authority
WO
WIPO (PCT)
Prior art keywords
bio
pin
cell
peptide
targeting
Prior art date
Application number
PCT/KR2012/001890
Other languages
English (en)
French (fr)
Other versions
WO2012124998A2 (ko
Inventor
정지형
장양수
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020110022984A external-priority patent/KR101300666B1/ko
Priority claimed from KR1020110055008A external-priority patent/KR101332621B1/ko
Priority claimed from KR1020110055007A external-priority patent/KR20120136034A/ko
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Priority to JP2013558789A priority Critical patent/JP5968343B2/ja
Priority to US14/005,047 priority patent/US9110059B2/en
Priority to EP12758083.5A priority patent/EP2708561A4/en
Publication of WO2012124998A2 publication Critical patent/WO2012124998A2/ko
Publication of WO2012124998A3 publication Critical patent/WO2012124998A3/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0097—Cells, viruses, ghosts, red blood cells, viral vectors, used for imaging or diagnosis in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

본 발명은 바이오핀에 관한 것으로, 보다 상세하게는, 세포막 단백질을 중심으로 세포 침투 펩타이드 또는 점착 펩타이드를 일 말단 또는 양 말단에 결합시킨 펩타이드성 복합체를 이용하여 세포 전달 및 치료, 세포의 추적, 특정 조직 및 세포의 표적화, 분자 영상 시스템, 의료도구 등에 사용할 수 있다.
PCT/KR2012/001890 2011-03-15 2012-03-15 바이오핀 WO2012124998A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2013558789A JP5968343B2 (ja) 2011-03-15 2012-03-15 バイオピン
US14/005,047 US9110059B2 (en) 2011-03-15 2012-03-15 Bio-pin
EP12758083.5A EP2708561A4 (en) 2011-03-15 2012-03-15 BIO-PIN

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR10-2011-0022984 2011-03-15
KR1020110022984A KR101300666B1 (ko) 2011-03-15 2011-03-15 바이오핀
KR10-2011-0055007 2011-06-08
KR1020110055008A KR101332621B1 (ko) 2011-06-08 2011-06-08 바이오핀
KR1020110055007A KR20120136034A (ko) 2011-06-08 2011-06-08 동시 진단 또는 치료용 융합 바이오 소재
KR10-2011-0055008 2011-06-08

Publications (2)

Publication Number Publication Date
WO2012124998A2 WO2012124998A2 (ko) 2012-09-20
WO2012124998A3 true WO2012124998A3 (ko) 2012-12-27

Family

ID=46831227

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/001890 WO2012124998A2 (ko) 2011-03-15 2012-03-15 바이오핀

Country Status (4)

Country Link
US (1) US9110059B2 (ko)
EP (1) EP2708561A4 (ko)
JP (1) JP5968343B2 (ko)
WO (1) WO2012124998A2 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10782302B2 (en) * 2012-05-04 2020-09-22 Wayne State University Detectors of serum biomarkers for predicting ovarian cancer recurrence
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
US11150251B2 (en) * 2016-10-07 2021-10-19 Clemson University Research Foundation Bi-functional arginine-glycine-aspartic acid (RGD) peptides and methods to promote angiogenesis
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
US12252582B2 (en) 2019-08-29 2025-03-18 University Of Delaware Biofunctional thiophene monomers and polymers thereof for electronic biomedical devices
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
WO2024181523A1 (ja) * 2023-02-28 2024-09-06 株式会社ノベルジェン 接着性及び機能性を有する組換えタンパク質並びにそれを含む組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
US20060263382A1 (en) 1998-06-20 2006-11-23 Richard Hotchkiss Membrane-permeant peptide complexes for treatment of sepsis
EP1297002A2 (en) 2000-06-30 2003-04-02 Board Of Regents, The University Of Texas System Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery
JP2007523050A (ja) * 2003-09-17 2007-08-16 カイアズマ・リミテッド 生物学的障壁を通した透過を容易にすることのできる組成物
WO2010002468A1 (en) * 2008-07-01 2010-01-07 The Trustees Of Columbia University In The City Of New York A functional complementation assay for defined gpcr oligomers
KR20110134939A (ko) * 2009-04-03 2011-12-15 더 맥클린 하스피털 코퍼레이션 유도된 다능성 줄기 세포
CN102580091B (zh) * 2011-01-12 2014-12-10 中国科学院上海生命科学研究院 增强阿片镇痛剂的镇痛作用的方法及试剂
WO2012153616A1 (ja) * 2011-05-10 2012-11-15 国立大学法人北海道大学 標的細胞移行能を有する脂質膜構造体、その製造方法および標的細胞において効果を示す物質のスクリーニング方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHOI, N. ET AL.: "The use of the fusion protein RGD-HSA-TIMP2 as a tumor targeting imaging probe for SPECT and PET", BIOMATERIALS, vol. 32, no. 29, 29 June 2011 (2011-06-29), pages 7151 - 7158, XP055066332 *
HE, S. Q. ET AL.: "Facilitation of µ-opioid receptor activity by preventing delta-opioid receptor-mediated codegradation", NEURON, vol. 69, no. 1, 13 January 2011 (2011-01-13), pages 120 - 131, XP028150805 *
MORRIS, M. C. ET AL.: "A peptide carrier for the delivery of biologically active proteins into mammalian cells", NATURE BIOTECHONOLOGY, vol. 19, no. 12, December 2001 (2001-12-01), pages 1173 - 1176, XP002559236 *
WADIA, J. S. ET AL.: "Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer", ADVANCED DRUG DELIVERY REVIEWS, vol. 57, no. 4, 19 December 2004 (2004-12-19), pages 579 - 596, XP004752189 *

Also Published As

Publication number Publication date
JP5968343B2 (ja) 2016-08-10
US9110059B2 (en) 2015-08-18
EP2708561A2 (en) 2014-03-19
JP2014514283A (ja) 2014-06-19
EP2708561A4 (en) 2014-09-24
WO2012124998A2 (ko) 2012-09-20
US20140256034A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
WO2012124998A3 (ko) 바이오핀
NZ603200A (en) Peptides and their use
WO2011150133A3 (en) Fibronectin based scaffold proteins having improved stability
WO2010141417A3 (en) Systems and methods for impairing smooth muscle tissue function
WO2012170911A3 (en) Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
WO2011143624A3 (en) Humanized and chimeric monoclonal antibodies to cd47
MY156286A (en) Human il-23 antigen binding proteins
BRPI1015424A2 (pt) métodos e composições utilizando peptídeos e proteínas com elementos de terminação c.
EP3915582A3 (en) Anti-cd277 antibodies and uses thereof
WO2012142591A3 (en) Compositions, methods and uses for multiplex protein sequence activity relationship mapping
WO2012083302A3 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
CA2801009C (en) Native wharton's jelly stem cells and their purification
WO2010093627A3 (en) Fibronectin type iii domain based scaffold compositions, methods and uses
WO2011126864A3 (en) Cancer treatment with recombinant vector
WO2010085100A3 (ko) 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
MX2013013996A (es) Tratamiento contra el dolor utilizando celulas madre placentarias.
WO2012008860A3 (en) Bacterial nitroreductase enzymes and methods relating thereto
PH12014501363A1 (en) Anticancer fusion protein
WO2012046084A3 (en) Short rna molecules
GB201001602D0 (en) Oligopeptidic compounds and uses therof
WO2012047951A3 (en) Human lung stem cells and uses thereof
WO2011049914A3 (en) Anti-hiv peptides and methods of use thereof
WO2012087160A3 (en) Anti-inflammatory proteins and methods of preparation and use thereof
WO2009155556A3 (en) Crkl targeting peptides
NZ610620A (en) Inhibitors of apoptosis and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12758083

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013558789

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2012758083

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012758083

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14005047

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载